Board of Directors

Tom Schnettler is vice chairman of Piper Sandler Companies, President of Piper Sandler Investment Group and managing director in the merchant banking group, as well as a member of the general partner. In his merchant banking role, Schnettler serves as co-CEO of PSC Capital Partners LLC, the registered investment adviser to the Piper Sandler merchant banking private funds. He initiated the merchant banking business at Piper Sandler in 2008 and has overseen the division since that time. Schnettler also served as president and chief operating officer of Piper Sandler from 2008 to 2011, and as chief financial officer between 2006 and 2008. Prior to that, Schnettler served as head of the Piper Sandler corporate and institutional services business beginning in 2002, and as head/co-head of investment banking beginning in 2000. From 1989 to 2000, he co-founded and led the healthcare investment banking group. Schnettler joined the Piper Sandler investment banking group in 1986.

Schnettler has served on the board of the following portfolio companies: Paragon 28, Akoya Biosciences, Elligo Health Research, Sapphire Digital, and Sport Ngin.

Schnettler graduated from Saint John’s University in Collegeville, Minnesota and holds a Juris doctorate from Harvard Law School.

Alf Grunwald has served as a member of our board of directors since February 2017. Since October 2015, he has served as the Chief Executive Officer of Black Forest One GmbH & Co KG and Managing Director of Black Forest Medical Holding GmbH, which are part of the Biedermann Group, and as the Chief Executive Officer of artprivat GmbH, an independent investment advisory firm. From 2006 to 2016, Mr. Grunwald served as an Associate Professor at the University of Applied Science Offenburg. From 2004 to 2015, he worked as both an independent management consultant and as a consultant for Techno Cap GmbH, which he founded. Prior to that, he served as a venture partner and then a partner at E.M. Warburg Pincus LLC from 1997 to 2004, and held various positions at Deloitte from 1995 to 1999, where he ultimately served as CEO and President of the ICS group and as a Senior Executive Advisor. Mr. Grunwald also founded T.L. Onyx Inc. in 1995, where he served as the chairman from 2002 to 2007. Mr. Grunwald has served as a director of LIM Innovations, Inc., a prosthetic socket technology company, since June 2017. He previously served as a director of Nemaris lnc., a surgical planning software company, EonTec Inc., an enterprise software provider, APP Group, a management consulting firm, Shinka Technologies, an information technology and services company, Synquest, a supply chain 151 management company, and RadNet Inc., an information technology company. Mr. Grunwald earned a degree in engineering from University of Applied Science Offenburg. We believe Mr. Grunwald is qualified to serve on our board of directors due to his broad leadership skills and extensive strategic advising experience.

Scott W. Drake is currently Chief Executive Officer, President, and Board Member of ViewRay (Nasdaq: VRAY). Mr. Drake has over 30 years of experience in the private and public sectors of the medical device field. From 2011 to August 2017, he served as President and Chief Executive Officer and as a member of the board of directors of The Spectranetics Corporation (formerly Nasdaq: SPNC), a medical device company; during his six-year tenure at Spectranetics, shareholder value increased from approximately $170 million to $2.2 billion. From 2009 to July 2011, he was a Senior Vice President of DaVita Corporation (NYSE: DVA), a provider of kidney care and dialysis. For 17 years, Mr. Drake held several positions of increasing responsibility within various healthcare business units at Covidien, Plc, including President of Covidien’s Respiratory and Monitoring Solutions Global Business. In addition, he served as Chairman of the Board for AtriCure Inc. (Nasdaq: ATRC) and as Chairperson of the Radiation Therapy Sector with AdvaMed. Mr. Drake has also served on the board of directors for Zayo Group Holdings, Inc. (NYSE: ZAYO), Bolder Surgical, and the Medical Device Manufacturers Association (MDMA). He currently serves on the board of directors of privately held medical device manufacturers, Cordis Corporation, and Paragon 28, Inc. Mr. Drake is an Ernst & Young 2014 Entrepreneur of The Year™ and holds a B.S. in Business Administration from Miami University of Ohio.

Steve has worked on VC and PE investments as venture partner or advisor with NEA, EQT, Temasek, and Cathay Capital. Previously, Steve served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic Steve served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.

In addition to Paragon 28, Steve currently serves on public boards for Baxter International, Sigilon Therapeutics and Peijia Medical (Hong Kong). He also serves on the boards for CeramTec (German industrial company) owned by private equity groups CPPIB and BC Capital, SHL Medical AG (EQT private equity), a market leader in auto-injectors for biologics and VC backed, Alcyone Therapeutics – targeted gene therapy for the CNS. He is also on the advisory boards for Alphabet’s Verily, and G2 Bio, a Temasek backed gene therapy incubator. Steve graduated summa cum laude from Harvard and received his medical degree from Yale: he completed his internship and residency at Massachusetts General Hospital.

Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.

Albert DaCosta is a veteran in the Foot & Ankle marketplace with over 14 years of experience and a passion directed toward discovering the optimal way to treat patients with lower extremity ailments. His obsession drives him to surround himself with like-minded people and build teams that work tirelessly to advance the science of our segment. Prior to establishing P28, Albert was a distributor for both Pioneer Surgical and Biomet Sports Medicine with responsibility spanning 12 states. Mr. DaCosta served as the Director of Biologics & Extremities for Wright Medical. He served as President of Non-Invasive Solutions, a company focused on lithotripsy for plantar fasciitis and lateral epicondylitis in 2005 as well as President & Founder of Body Beautiful Laser Centers in South Florida in 2006.

Albert earned a B.S. in Chemical Engineering from the University of Florida with a minor in Business.

Kristina Wright has served as a member of our board of directors since December 2021. Ms. Wright has served as Vice President and General Manager of the Brain Modulation business of Medtronic, plc, a medical device company since December 2021. She previously was Vice President and Chief Financial Officer for the Neuromodulation Operating Unit of Medtronic, plc, in both finance and corporate development since July 2020 and has held various leadership positions at Medtronic, plc, in both finance and corporate development since August 2010. Prior to Medtronic, plc, Ms. Wright worked at PricewaterhouseCoopers, LLC, in the Audit and Assurance and Transaction Services practices from 1999 to 2010. Ms. Wright holds a B.S.in Accounting from the University of Minnesota, and an M.B.A. from the Fuqua School of Business at Duke University.

B. Kristine Johnson has served as a member of our board of directors since December 2021. Ms. Johnson has been President and General Partner of Affinity Capital Management, a venture capital firm, since 2000. In April 2021, she was appointed Chairperson of the board of directors of AtriCure, Inc. (Nasdaq: “ATRC”), a medical device company, where she also served as a member of the board of directors since March 2017. Ms. Johnson has served as a member of the board of directors of ViewRay, Inc. (Nasdaq: “VRAY”), a company that develops radiation therapy technology, since April 2020, and ClearPoint Neuro, Inc. (Nasdaq: “CLPT”), a medical device company, since August 2019. She served as a member of the board of directors of Piper Sandler, an investment banking firm, from 2003 to 2019, where she was lead director from 2012 to 2018. Ms. Johnson served as a member of the board of directors of The Spectranertics Corporation (Nasdaq: “SPNC”), a medical device company from 2012 to 2017. She held various executive leadership positions at Medtronic, plc (NYSE: “MDT”) from 1982 to 1999. Ms. Johnson serves as a member of the board of directors of the University of Minnesota Foundation Investment Advisors, where she has served as chair since 2016. She graduated summa cum laude with a B.A. from St. Olaf College.

Meghan Scanlon has served as a member of our board of directors since April 2022. Ms. Scanlon has served as a Senior Vice President, Urology and Pelvic Health Division of Boston Scientific Corporation (NYSE: BSX), a medical device company since February 2020. She previously held various leadership positions at Boston Scientific, in global marketing and general management since September 2014. Prior to Boston Scientific, Ms. Scanlon worked at DePuy Synthes, Mitek Sports Medicine, the orthopedics company of Johnson and Johnson from July 2000 to September 2014. These experiences include driving global expansion and product launches, integrating multiple high growth acquisitions, directing high impact strategic and portfolio planning and leading high performing talent and DEI cultures. Ms. Scanlon holds a B.S in mechanical engineering from Tufts University, and both an M.B.A and a M.S. in Mechanical Engineering from the Massachusetts Institute of Technology.